



Introduction

Ulrich Keilholz

Charite Berlin, Germany



Disclosures

- Personal** Investigator on 3 ipilimumab trials
Immediate iSBT Past President
until 10:15 a.m. today
- iSBTc** No fundraising for Hot Topic Session
Fundraising to other programs
independent of Hot Topic Session



Why **Hot Topic Sessions?**

iSBTc Strategic Plan: Core Purpose

To improve patient outcomes by advancing the development and application of biological therapy / immunotherapy



Previous **Hot Topic Sessions**

2003	Patient-specific therapies
2007	The Dendreon-Debate
2008	Anti-CTLA-4



Why Anti-CTLA-4 Debate?

New class of biological agents, termed immune-checkpoint regulators.

New development paradigms required?

Can we learn from previously licensed biologicals for anti-CTLA-4 development?

Can we learn from anti-CTLA-4 development for future biologicals?



How to debate anti-CTLA-4?

Jeff Weber	Review of ipilimumab development plan
Antoni Ribas	Review of tremilimumab development plan
Mario Sznol	Comparison of development plans for IL-2 and anti-CTLA-4

Steven Hirschfeld Evaluation of IL-2 / CTLA-4 type activity data

Discussion - Discussion - Discussion - Discussion